Skip to main content

Table 2 Recent checkpoint inhibitor study results in melanoma

From: Novel melanoma therapy

Study Phase of study Prior Tx Agent ORR (%) PFS OS
[25] I Yes/no Pembrolizumab 31–51 >7 months NA
[5] I Yes Pembrolizumab 26 37–45 % at 6 months 58–63 % at 1 year
[26] II Yes Pembrolizumab 21–25 34–38 % at 6 months NA
Chemotherapy 4 16 % at 6 months
[27]
[28]
I/II Yes/no Pembrolizumab 33 35 % at 1 year 23 months
40 % at 3 years
[29]
[30]
III No Pembrolizumab 32.9–33.7 46.4-47.3 % at 6 months 55 % at 2 years
Ipilimumab 11.9 26.5 % at 6 months 43 % at 2 years
[6] I Yes Nivolumab 31 27 % at 2 years 16.8 months
43 % at 2 years
[32] III No Nivolumab 40.0 5.1 months 72.9 % at 1 year
DTIC 13.9 2.2 months 42.1 % at 1 year
[33] III Yes Nivolumab 31.7 48 % at 6 months NA
Chemotherapy 10.6 34 % at 6 months
  1. Prior Tx patients with prior treatment for metastatic melanoma included. Yes/No indicates a mixed population of treatment naïve and pre-treated patients